• Topics

  • Formats

Speaker(s): Dr. Sally Dowen

Demonstrating the UK’s regulatory advantage over the EU for first-in-human and early-phase clinical trials

Why Attend:

  • A comparison of the UK and EU regulatory environments for early-phase trials
  • Why bring your early-phase trials to the UK
  • How Nucleus Network can support your early-phase drug development

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?